Literature DB >> 23027047

Engineering small interfering RNAs by strategic chemical modification.

Jesper B Bramsen1, Jørgen Kjems.   

Abstract

Synthetic small interfering RNAs (siRNAs) have revolutionized functional genomics in mammalian cell cultures due to their reliability, efficiency, and ease of use. This success, however, has not fully translated into siRNA applications in vivo and in siRNA therapeutics where initial optimism has been dampened by a lack of efficient delivery strategies and reports of siRNA off-target effects and immunogenicity. Encouragingly, most aspects of siRNA behavior can be addressed by careful engineering of siRNAs incorporating beneficial chemical modifications into discrete nucleotide positions during siRNA synthesis. Here, we review the literature (Subheadings 1 -3) and provide a quick guide (Subheading 4) to how the performance of siRNA can be improved by chemical modification to suit specific applications in vitro and in vivo.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23027047     DOI: 10.1007/978-1-62703-119-6_5

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  14 in total

1.  Direct Pharmacological Inhibition of β-Catenin by RNA Interference in Tumors of Diverse Origin.

Authors:  Shanthi Ganesh; Martin L Koser; Wendy A Cyr; Girish R Chopda; Junyan Tao; Xue Shui; Bo Ying; Dongyu Chen; Purva Pandya; Edmond Chipumuro; Zakir Siddiquee; Kevin Craig; Chengjung Lai; Henryk Dudek; Satdarshan P Monga; Weimin Wang; Bob D Brown; Marc T Abrams
Journal:  Mol Cancer Ther       Date:  2016-07-07       Impact factor: 6.261

2.  Synthesis and Biological Activity of Short Interfering RNAs Having Several Consecutive Amide Internucleoside Linkages.

Authors:  Venubabu Kotikam; Julien A Viel; Eriks Rozners
Journal:  Chemistry       Date:  2019-12-17       Impact factor: 5.236

Review 3.  Recent advances in targeted delivery of non-coding RNA-based therapeutics for atherosclerosis.

Authors:  Xiaoxin Li; Hongzhao Qi; Weigang Cui; Zhibin Wang; Xiuxiu Fu; Tianxiang Li; Huibo Ma; Yanyan Yang; Tao Yu
Journal:  Mol Ther       Date:  2022-08-01       Impact factor: 12.910

Review 4.  Antisense Oligonucleotides and Small Interfering RNA for the Treatment of Dyslipidemias.

Authors:  Clarice Gareri; Alberto Polimeni; Salvatore Giordano; Laura Tammè; Antonio Curcio; Ciro Indolfi
Journal:  J Clin Med       Date:  2022-07-04       Impact factor: 4.964

Review 5.  RNA interference-based therapy and its delivery systems.

Authors:  Xiuhui Chen; Lingegowda S Mangala; Cristian Rodriguez-Aguayo; Xianchao Kong; Gabriel Lopez-Berestein; Anil K Sood
Journal:  Cancer Metastasis Rev       Date:  2018-03       Impact factor: 9.264

6.  Tumor-targeted in vivo gene silencing via systemic delivery of cRGD-conjugated siRNA.

Authors:  Xiaoxia Liu; Wei Wang; Dmitry Samarsky; Li Liu; Qian Xu; Wenqing Zhang; Guangzu Zhu; Ping Wu; Xialin Zuo; Houliang Deng; Jingjing Zhang; Zhuomin Wu; Xiaohui Chen; Lingfeng Zhao; Zhiyong Qiu; Zhongyi Zhang; Qiyi Zeng; Wei Yang; Biliang Zhang; Aimin Ji
Journal:  Nucleic Acids Res       Date:  2014-09-15       Impact factor: 16.971

Review 7.  The notorious R.N.A. in the spotlight - drug or target for the treatment of disease.

Authors:  Philipp Reautschnig; Paul Vogel; Thorsten Stafforst
Journal:  RNA Biol       Date:  2016-07-14       Impact factor: 4.652

8.  Short-interference RNAs: becoming medicines.

Authors:  Tamara Martínez; Ana Isabel Jiménez; Covadonga Pañeda
Journal:  EXCLI J       Date:  2015-06-15       Impact factor: 4.068

Review 9.  siRNA Versus miRNA as Therapeutics for Gene Silencing.

Authors:  Jenny K W Lam; Michael Y T Chow; Yu Zhang; Susan W S Leung
Journal:  Mol Ther Nucleic Acids       Date:  2015-09-15       Impact factor: 10.183

10.  Amide linkages mimic phosphates in RNA interactions with proteins and are well tolerated in the guide strand of short interfering RNAs.

Authors:  Daniel Mutisya; Travis Hardcastle; Samwel K Cheruiyot; Pradeep S Pallan; Scott D Kennedy; Martin Egli; Melissa L Kelley; Anja van Brabant Smith; Eriks Rozners
Journal:  Nucleic Acids Res       Date:  2017-08-21       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.